EZH2 and cancer: Countering the induction of EZH2 expression in T cells by SLAMF7 signaling (which can be prevalent in the TME of certain cancers (O’Connell et al., 2021)) are unknown factors in the TME which negatively regulate EZH2 levels (Stairiker et al., 2020).